Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: IMA203 emerges as a Novel Investigational Agent in Cutaneous Melanoma: With Justin Moser, MD
Description: In today’s episode, supported by Immatics, we had the pleasure of speaking with Justin Moser, MD, about the ongoing phase 3 SUPRAME trial investigating the PRAME-directed T-cell receptor T-cell therapy IMA203 vs treatment of physician's choice in patients with previously treated, unresectable or metastatic cutaneous melanoma. Dr Moser is an associate clinical investigator, a melanoma and cutaneous oncology specialist, and a phase 1 trialist at HonorHealth Research Institute in Scottsdale, Arizona; as well as a research associate professor at the Arizona State University School of Medicine and Advanced Medical Engineering.In our exclusive interview, Dr Moser discussed the unique me...